Featured Research

from universities, journals, and other organizations

Growing use of clinical registry data for post-market device surveillance

Date:
September 26, 2013
Source:
Society of Thoracic Surgeons
Summary:
Signifying an increasing confidence in clinical outcomes registries, the U.S. Food and Drug Administration has approved expanded labeling for the Edwards SAPIEN Transcatheter Heart Valve, making the device available to a larger group of patients with aortic stenosis.

Signifying an increasing confidence in clinical outcomes registries, the U.S. Food and Drug Administration has approved expanded labeling for the Edwards SAPIEN Transcatheter Heart Valve, making the device available to a larger group of patients with aortic stenosis, a heart valve disease that causes narrowing of the aortic valve, restricting blood flow from the heart.

In announcing its decision on Monday to approve the expanded device labeling, the agency cited data from The Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry, as well as FDA-approved clinical studies and peer-reviewed medical journals.

"Less than 2 years after transcatheter heart valve therapy became available for a very select patient population, the STS/ACC TVT Registry supplied the needed data to support label expansion," said STS President Douglas E. Wood, MD. "We are thrilled that more patients will now have access to this life-saving therapy."

ACC President John G. Harold, MD, MACC concurred. "The FDA's decision to make this device available to an expanded group of patients highlights the value of the TVT Registry," Dr. Harold said. "This decision demonstrates the efficiency of rigorous clinical registries, which allowed the FDA to make a prompt decision that will impact thousands of patients who previously would not have had access to this procedure."

Importance of Clinical Registries

The TVT Registry, launched in 2011, is a benchmarking tool developed to track patient safety and real-world outcomes involving transcatheter aortic valve replacement (TAVR). When TAVR was first approved, it was for device insertion using only the transfemoral approach (via an artery from the leg) in inoperable patients. The labeled indication was subsequently extended to high-risk, operable patients using either a transfemoral or transapical (between the ribs through the tip of the heart) approach; however, that still left a significant number of patients who were unable to be treated -- patients who were inoperable and not able to be treated by a transfemoral approach and high-risk or inoperable patients who would be best treated by another "alternative" approach.

The TVT Registry supplied the FDA with data collected from several thousand alternative access procedures showing no evidence that the device performed differently or had a different benefit-risk profile when alternative access approaches were used.

First-year outcomes from the TVT Registry are expected to be published later this year, and Edwards and the FDA will continue to monitor all short- and long-term patient outcomes with the SAPIEN device.

"More patients are anticipated to benefit based on the ability of physicians and hospitals participating in the TVT Registry to collect timely and accurate data and the ACC's and STS's ability to promptly provide outcomes information to regulatory agencies and device manufacturers," said Michael J. Mack, MD, STS Past President and Chair of the STS/ACC TVT Registry Steering Committee.

"The collaborative relationship between the professional societies, the FDA, and CMS in developing the TVT Registry for monitoring continued safety and efficacy of the transformational technology of TAVR will allow optimal management of care for an increasing number of patients suffering from aortic stenosis," said David Holmes, MD, ACC Past President and Vice Chair of the STS/ACC TVT Registry Steering Committee. "This development provides opportunity for care of high-risk patients who were previously not treated."

Future of the STS/ACC TVT Registry

The STS/ACC TVT Registry will continue to provide robust, real-time information for better post- market device surveillance and will serve as a platform for future potential investigational device exemption studies, such as one involving valve-in-valve procedures.

"Data from the TVT Registry provide a unique opportunity to evaluate current clinical practice and patient outcomes" said STS Research Center Director Fred Edwards, MD. "We are hopeful that this level of collaboration and use of registries will continue to fuel innovations for the medical device approval process in the United States."

Currently, 248 US institutions are enrolled in the TVT Registry. The institutions are located across 45 states and the District of Columbia.


Story Source:

The above story is based on materials provided by Society of Thoracic Surgeons. Note: Materials may be edited for content and length.


Cite This Page:

Society of Thoracic Surgeons. "Growing use of clinical registry data for post-market device surveillance." ScienceDaily. ScienceDaily, 26 September 2013. <www.sciencedaily.com/releases/2013/09/130926122403.htm>.
Society of Thoracic Surgeons. (2013, September 26). Growing use of clinical registry data for post-market device surveillance. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/09/130926122403.htm
Society of Thoracic Surgeons. "Growing use of clinical registry data for post-market device surveillance." ScienceDaily. www.sciencedaily.com/releases/2013/09/130926122403.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins